A Phase I study of the Heat Shock Protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors

PURPOSE: A Phase I study to define toxicity and recommend a Phase II dose of the HSP90 inhibitor alvespimycin (17-DMAG; 17-dimethylaminoethylamino-17-demethoxygeldanamycin). Secondary endpoints included evaluation of pharmacokinetic profile, tumor response and definition of a biologically effective...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Pacey, Simon, Wilson, Richard H., Walton, Mike, Eatock, Martin M., Hardcastle, Anthea, Zetterlund, Anna, Arkenau, Hendrik-Tobias, Moreno-Farre, Javier, Banerji, Udai, Roels, Belle, Peachey, Heidi, Aherne, Wynne, de Bono, Johan S., Raynaud, Florence, Workman, Paul, Judson, Ian
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3060938/
https://ncbi.nlm.nih.gov/pubmed/21278242
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-1927
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados